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Tumors are wickedly clever. They turn our would-be allies of the immune system against us—
manipulating Tregs, seducing stromal cells to eliminate cytotoxic T cells, and recruiting specialized
macrophages to modify the microenvironment. Recent advances liberate our most highly trained
warriors from cancer’s grasp and bring them back to our side.CD8+ cytotoxic lymphocytes (red) interact with
CD4+ Foxp3+ regulatory T cells (CD4 is shown
as a green ring surrounding Foxp3 labeled
blue in the nucleus). Images courtesy of Fabien
Garc¸on.Repurposing Inhibitors to Restrain Tregs
Tumors anda fully armed immune systemdonot get along. To shield themselves
from external attack, tumor cells induce an immune-suppressive local environ-
ment, and regulatory T cells (Tregs) are their favorite targets. Ali et al. (2014)
discover that PI(3)K p110d is a focal point of attack. The authors first examine
the effect of p110d genetic inactivation on cancer development in mice, and
they observe a strong inhibition on both tumor growth andmetastasis in various
tumor models. A closer look at the immune system reveals that p110d inactiva-
tion preferentially impairs themaintenance and activity of Tregs in the periphery,
rendering tumors vulnerable to the attack of cytotoxic T lymphocytes (CTLs).
Interestingly, p110d inhibitors have recently been shown highly effective in
treating patients with certain types of leukemia and lymphoma, presumably
through targeting cancer-stroma crosstalk. The authors now find that treatment
with these inhibitors fully recapitulates the beneficial effect of p110d inactivation
in their models, not only indicating the potential of repurposing these clinically
effective drugs for treating various solid tumors but also providing valuable
insights on the role of p110d in modulating immune environment in the tumor
context. Notably, a mild defect of differentiation from CD8+ T cells to fully
competent CTLs is observed with the treatment. Strategies to further minimize
the impact of p110d inhibitors on CD8+ T cell differentiation while restraining
Treg activity may be a future direction to pursue.
Ali, K., et al. (2014). Nature 510, 407–411.FasL (brown) is expressed by endothelium of
tumors (right) and is absent from normal tissues
(left) in an ovarian cancer patient. Image cour-
tesy of G. Motz.Tumor Tolerance Is FasL’s Fault
Recent evidence indicates that the tumor endothelium, rather than being a
simple physical barrier for all T cell infiltration, is a gatekeeper that permits
the passage of Tregs while preventing the entry of CD8+ T cells. A study by
Motz et al. (2014) shows that this selectivity is achieved by FasL expression
in the tumor microenvironment. Interestingly, in a variety of human solid tumor
samples analyzed, FasL upregulation is relatively specific to the endothelium,
as opposed to the bulk of tumor cells. However, further investigation reveals
the instructive role of tumor cells behind the scene—it is the soluble factors
secreted by them, including IL-10, PGE2, and VEGF-A, that are responsible
for the FasL induction in tumor endothelium. Elevated FasL in turn leads to a
preferential accumulation of Tregs in tumors by exerting a selective toxicity
on CD8+ effector T cells. To explore the therapeutic potential of targeting
this mechanism, the authors test the efficacy of inhibiting FasL upregulation using pharmacological reagents, and they
find that the combinatory approach of inhibiting PGE2 production with FDA approved drugs and neutralizing VEGF-A activity
by the G6-31 antibody is sufficient for blocking FasL elevation. This intervention promotes the local immunity over tumor-sup-
pressing CD8+ T cells, thereby significantly suppressing tumor growth in a number of in vivo mouse models. This work high-
lights the importance of interfering with the communication between tumor cells and the endothelium for cancer suppression.
It also points out that simultaneously targeting angiogenesis and modifying tumor immune environment could be a promising
strategy for cancer therapy.
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Schematic representation (left) of the
CSF-1R ECD dimer, and the overall
structure of the CSF-1R ECD monomer
complex with Fab fragment of RG7155
(right). Image courtesy of C. Ries.Wham! Bam! Anti-TAM!
In many types of solid tumors, infiltration of tumor-associated macrophages (TAMs)
is a warning sign for poor prognosis. As a core component of the tumor microenviron-
ment, TAMs exert an immunosuppressive function that promotes tumor develop-
ment, making them a promising target for therapeutic development. Ries et al.
(2014) generate a monoclonal antibody (RG7155) against human CSF-1R, targeting
colony-stimulating factor 1 (CSF-1) signaling that is essential formacrophage survival.
RG7155 works by specifically blocking the dimerization interface of CSF-1R, thereby
inhibiting both ligand-dependent and ligand-independent activation of the receptor
while sparing other human type III receptor tyrosine kinases. The specificity is
confirmed by the selective toxicity of the antibody toward immunosuppressive
TAMs without harming proinflammatory M1-like macrophages in vitro. After carefully
examining the pharmacokinetic and pharmacodynamics profiles of RG7155 in
nonhuman primates, the investigators apply the antibody treatment to patients with
diffuse-type giant cell tumors (Dt-GCT) and patients with various advance solid
tumors. The results are encouraging. Not only does the CD8+/CD4+ T cell ratio inthe tumor environment change significantly, indicating a boosted response against tumor cells, but a beneficial metabolic
response is also observed in DT-GCT patients by FDG-PET imaging, demonstrating substantial clinical efficacy of targeting
TAMs. In adding TAM targeting to our therapeutic arsenal, it will be important to bear in mind that in some tumors, for instance
colorectal cancer, TAMs are associated with good prognosis, and so its deployment will likely make sense for some
battlefields but not others.
Ries, C.H., et al. (2014). Cancer Cell 25, 846–859.Lungmetastases in the patient prior (top)
and 6 months after treatment (bottom).
Image courtesy of S. Rosenberg.TH1 versus Cancer, It’s Personal
While cancer cells are infamous for their manipulative power to numb the immune sys-
tem, the intrinsic nature of their genome instability makes it possible for them to
randomly generate new epitopes that the immune system is not familiar with.
In theory, this process could then create a personal cancer cell signature that trig-
gers a patient-specific antitumor response mediated by mutation-reactive T cells.
Rosenberg and his colleagues (2014) now demonstrate that this scenario is indeed
happening in epithelial cancer, which accounts for over 80% of human malignancies.
Most importantly, they successfully apply an adoptive T cell transfer strategy based
on this phenomenon on a patient with metastatic cholangiocarcinoma and achieve
an encouraging outcome. The researchers perform whole-exomic sequencing using
metastasis samples from the patient and identify a point mutation on ERBB2IP that
can be specifically recognized by a TH1 population within tumor-infiltrating lympho-
cytes from the patient. After bulk-expansion, this mutation-reactive TH1 population
is adoptively transferred back to the same patient who has received IL-2 treatment
to enhance T cell function. Remarkably, tumor regression is observed for over six
months after this single procedure, with polyfunctional TH1 cells readily detectable
in the blood stream. As straightforward as the rationale of this treatment is, adoptive
cell transfer has not been considered a promising strategy for epithelial cancer,
because of the low frequency of tumor-reactive T cells in these patients. This current
work clearly indicates otherwise and highlights the potential power of one’s endoge-
nous TH1 response for combating cancer.
Tran, E., et al. (2014). Science 344, 641–645.
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